Endocrine disruptor screening tests
This article was originally published in The Rose Sheet
Executive Summary
National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods makes available final report on Evaluation of In Vitro Test Methods for Detecting Potential Endocrine Disruptors, according to June 3 Federal Register 1notice. Report features ICCVAM's recommendations on minimum procedural standards for standardization and validation of in vitro estrogen and androgen receptor binding and transcriptional activation assays, NICEATM says. Document also includes list of substances, including three phthalates, proposed for validation of the screening methods. In October, NICEATM solicited comments on an expert panel report on the status of in vitro endocrine disruptor methods (2"The Rose Sheet" Oct. 28, 2002, In Brief)...
You may also be interested in...
ICCVAM
Addendum to the ICCVAM Evaluation of In Vitro Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays published in a March 16 Federal Register notice includes recommendation by Interagency Coordinating Committee on the Validation of Alternative Methods to replace four substances that are not commercially available or have restricted availability - anastrazole, CGS 18320B, fadrozole and ICI 182,780 - with 4-hydroxyandrostenedione, chrysin, dicofol and raloxifene HCl. ICCVAM published final report containing minimum procedural standards for standardization and validation of in vitro estrogen and androgen receptor binding and transcriptional activation assays in 2003 (1"The Rose Sheet" June 16, 2003, In Brief). Comments on addendum, which also identifies six other substances that could be replaced, are due May 1...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.